ARTICLE

Received 10 Sep 2013 | Accepted 28 Apr 2014 | Published 9 Jun 2014

DOI: 10.1038/ncomms4970

MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2

Rabea Hinkel^{1,2,*}, Teresa Trenkwalder^{1,2,3,*}, Björn Petersen⁴, Wira Husada¹, Florian Gesenhues¹, Seungmin Lee¹, Ewald Hannappel⁵, Ildiko Bock-Marquette^{6,7}, Daniel Theisen⁸, Laura Leitner⁹, Peter Boekstegers¹, Czeslaw Cierniewski¹⁰, Oliver J. Müller^{11,12}, Ferdinand le Noble^{13,14}, Ralf H. Adams¹⁵, Christine Weinl¹⁶, Alfred Nordheim¹⁶, Bruno Reichart^{2,3}, Christian Weber^{2,17}, Eric Olson⁶, Guido Posern^{8,18}, Elisabeth Deindl³, Heiner Niemann⁴ & Christian Kupatt^{1,2,3}

Gradual occlusion of coronary arteries may result in reversible loss of cardiomyocyte function (hibernating myocardium), which is amenable to therapeutic neovascularization. The role of myocardin-related transcription factors (MRTFs) co-activating serum response factor (SRF) in this process is largely unknown. Here we show that forced MRTF-A expression induces CCN1 and CCN2 to promote capillary proliferation and pericyte recruitment, respectively. We demonstrate that, upon G-actin binding, thymosin β 4 (T β 4), induces MRTF translocation to the nucleus, SRF-activation and CCN1/2 transcription. In a murine ischaemic hindlimb model, MRTF-A or T β 4 promotes neovascularization, whereas loss of MRTF-A/B or CCN1-function abrogates the T β 4 effect. We further show that, in ischaemic rabbit hindlimbs, MRTF-A as well as T β 4 induce functional neovascularization, and that this process is inhibited by angiopoietin-2, which antagonizes pericyte recruitment. Moreover, MRTF-A improves contractile function of chronic hibernating myocardium of pigs to a level comparable to that of transgenic pigs overexpressing T β 4 (T β 4tg). We conclude that MRTF-A promotes microvessel growth (via CCN1) and maturation (via CCN2), thereby enabling functional improvement of ischaemic muscle tissue.

¹ Medizinische Klinik und Poliklinik I, Klinikum Grosshadern, 81377 Munich, Germany. ² DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, 80802 München, Germany. ³ Walter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilians University, 81377 München, Germany. ⁴ Institute of Farm, Animal Genetics, Friedrich-Loeffler-Institute, 31535 Neustadt a.Rbge, Germany. ⁵ Institute for Biochemistry, Friedrich-Alexander University, 91054 Erlangen, Germany. ⁶ Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9148, USA. ⁷ Department of Biochemistry and Medical Chemistry, University of Pecs Medical School, H-7624 Pécs, Hungary. ⁸ Department of Clinical Radiology, University Clinic Grosshadern, 81377 Munich, Germany. ⁹ Max Planck Institute of Biochemistry, 82152 Martinsried, Germany. ¹⁰ Department of Molecular and Medical Biophysics, Medical University of Lodz, Lodz 93-232, Poland. ¹¹ Department of Cardiology, Internal Medicine III, University Hospital Heidelberg, 69120 Heidelberg, Germany. ¹² DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, 69120 Heidelberg, Germany. ¹³ Angiogenesis and Cardiovascular Pathology, Max-Delbrueck-Center for Molecular Medicine, 13092 Berlin, Germany. ¹⁴ DZHK (German Center for Cardiovascular Research), partner site Max-Delbrueck-Center, 13092 Berlin, Germany. ¹⁵ Department of Tissue Morphogenesis, Faculty of Medicine, Max Planck Institute for Molecular Biomedicine and University of Muenster, 48149 Muenster, Germany. ¹⁶ Department of Molecular Biology, Interfaculty Institute for Cell Biology, University of Tuebingen, 72076 Tuebingen, Germany. ¹⁷ Institute for Cardiovascular Prevention, Ludwig-Maximilians University, 80336 München, Germany. ¹⁸ Institute of Physiological Chemistry, Martin-Luther-University Halle-Wittenberg, 06114 Halle (Saale), Germany. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to C.K. (email: Christian.kupatt@med.uni-muenchen.de).

Chronic ischaemic disease of the heart or peripheral muscle is currently treated by surgical or interventional efforts to revascularize the stenosed or occluded vascular networks. However, within a growing patient population, conventional therapeutic strategies are exhausted and clinical benefit is expected from adjuvant neovascularization therapies (angiogenesis/arteriogenesis). Previous preclinical¹ and clinical studies² failed to demonstrate a gain of perfusion when enforcing angiogenesis (capillary growth) in the absence of microvessel maturation—that is, recruitment of pericytes and smooth muscle cells^{3,4}. Moreover, arteriogenesis (collateral growth), an essential element of flow improvement, did not prolong walking time in patients with critical limb ischaemia, when auxiliary granulocyte-macrophage colony-stimulating factor treatment was employed without induction of microvessel growth and stabilization⁵. In contrast, adaptive collateralization⁶ occurred when a pro-angiogenic factor such as vascular endothelial growth factor A (VEGF-A) was combined with the maturation factors platelet-derived growth factor-B¹ or Angiopoietin-1 (ref. 7). On the other hand, inhibition of NF κ B signalling, impairing VEGF-A and platelet-derived growth factor-B expression, led to a hyperbranched and immature collateral network⁸. Thus, an increase in stable and regulated microvessels is required to induce functional neovascularization.

Myocardin-related transcription factors (MRTFs) have been shown to activate serum response factor (SRF)^{9–11} upon dissociation from G-actin¹², providing muscle growth and regeneration^{13,14}. SRF is co-activated by myocardin¹⁵ or MRTFs A and B¹⁶. These SRF coactivators are interacting with G-actin and translocate to the nucleus¹⁷, when G-actin levels decrease, for example, due to sequestration by the G-actin-binding peptide thymosin β 4 (T β 4)^{18–20}. Since T β 4 is a potent pro-angiogenic factor²¹, an involvement of the T β 4-MRTF-SRF axis in vascular growth would require transcriptional activation beyond well-known myogenic proteins^{13,14}. However, MRTF coactivation of SRF induces pro-angiogenic factors such as CCN1 (Cyr61)²² and maturation factors such as connective tissue growth factor (CTGF)^{23,24}. Moreover, SRF controls tip cell behaviour in angiogenesis^{25,26}, indicating a role of MRTF-SRF in vascular growth and maintenance.

In the current study, we sought to investigate the capability of MRTF-A and its upstream activator, T β 4, to induce functional vascular regeneration after prolonged ischaemia. We found that both T β 4 as well as MRTF-A increase the SRF-dependent genes *CCN1* and *CCN2*, and induce capillary growth and maturation *in vivo*. Of note, the microvascular alterations were followed by adaptive collateralization in rabbit hindlimb ischaemia and porcine chronic hibernating myocardium. In the latter model we could demonstrate that both, perfusion and function of the ischaemic myocardium, improve upon T β 4 or MRTF-A overexpression.

Results

T β 4 and MRTF-A induce CCN1 and CCN2 *in vitro*. We found (Fig. 1a–d) that MRTF-A induced hallmarks of angiogenesis—that is, migration and tube formation of cultured human microvascular endothelial cells—to a similar extent as T β 4. The pro-angiogenic effect of MRTF-A was dependent on the G-actin-binding motif of T β 4, as mutating this domain and annihilating G-actin binding abolished the T β 4 effect on vessel growth, as did a short-hairpin RNA (shRNA) interfering simultaneously with MRTF-A and B transcription (MRTF-shRNA)²⁷. Consistently, T β 4 enhanced nuclear MRTF-A translocation (Fig. 1e, Supplementary Fig. 1a,b), as well as transcription of an MRTF/SRF-dependent reporter gene containing three

SRF-binding sites of the c-fos promoter (p3DA.Luc, Fig. 1f)²⁸. Both, MRTF-A and T β 4, induced expression of genes involved in microvessel growth, most notably *CCN1*, mediating angiogenesis²⁹ and *CCN2*, relevant for 10T1/2 pericyte-like cell attraction²⁴ (Supplementary Fig. 1c–g). Of note, T β 4 transfection did not affect MRTF-A content (Supplementary Fig. 1h), unlike MRTF-A transfection. In line with *CCN1/2* being downstream of MRTFs and relevant for vessel formation, interference with *CCN1*-shRNA prevented T β 4-induced tube formation (Fig. 1g), whereas *CCN2*-shRNA interrupted attachment of a murine pericyte-like cell line (C3H/10T1/2) to endothelial tubes *in vitro* (Fig. 1h–i).

Role of MRTFs in Thymosin β 4-induced neovascularization.

To further demonstrate the relevance of MRTF signalling *in vivo*, we used a murine hindlimb ischaemia model. Intramuscular (i.m.) injection of recombinant adeno-associated virus (AAV) vectors (rAAVs, Supplementary Fig. 2a–c) raised tissue concentration of target proteins in the treated limb (Fig. 2a) and transcript levels of the downstream mediators *CCN1* and *CCN2* (Fig. 2b, Supplementary Fig. 2d–f). Consistently, rAAV.MRTF-A induced capillary growth (Fig. 2c,d) and increased perfusion at d7 (Fig. 2e,f). As an upstream activator, T β 4 had a similar effect on vessel growth and function (Fig. 2c–f), unless the G-actin-binding motif was lacking (T β 4 m) or an rAAV.MRTF-shRNA was co-applied. To further assess the relevance of MRTFs in T β 4-induced vessel growth, rAAV.Cre was applied to *Mrtf-a*^{−/−} *Mrtfb*^{flx/flx} hindlimbs in order to cause MRTF-A and -B double deficiency. In Cre-induced MRTF-A/B knockouts, T β 4 was unable to stimulate capillary growth (Fig. 2g), pericyte recruitment (Supplementary Fig. 2g,h) and improve perfusion (Fig. 2h, Supplementary Fig. 2i) at d7 after ischaemia induction. Similarly, when rAAV.Cre was applied to *CCN1*^{flx/flx} mice, hindlimbs did not display T β 4-mediated gains of either capillaries (Fig. 2i,j) or perfusion at d7 (Fig. 2k,l). Thus, MRTF-A transduction or MRTF activation via T β 4-mediated G-actin sequestration stimulate transcription of *CCN1* to mediate functional vascular regeneration.

MRTFs induced pericyte recruitment and collateral growth.

The interdependence of microcirculatory growth and arteriogenesis for the mediation of flow recovery was assessed in a rabbit ischaemic hindlimb model (Supplementary Fig. 3a), which is compatible with topic separation of the microvessel growth area (lower limb) and the collateralization area (upper limb). Regional transduction of the ischaemic calf muscles with MRTF-A or T β 4 via rAAV (Fig. 3a, Supplementary Fig. 3b–d) led to functional neovascularization including CD31⁺ capillary sprouting, NG2⁺ pericyte investment (Fig. 3b–d) and collateral growth (Fig. 3e,f). Of note, MRTF activation via T β 4 transduction of the thigh region, although capable of inducing a modest collateral growth, did not increase perfusion, whereas restricting MRTF activation via T β 4 to the calf region sufficed to significantly stimulate micro- and macrovascular growth as well as perfusion (Supplementary Fig. 3e–i). Detachment of microvascular pericytes by forced Angiopoietin-2 expression (Fig. 3b–d) abrogated the T β 4- and MRTF-A-mediated collateralization and flow improvement (Fig. 3e–g). Moreover, blocking flow-induced vasodilation by oral application of L-NAME, an unselective nitric oxide synthase inhibitor, did not affect capillary growth and maturation (Supplementary Fig. 3j) but prevented collateral formation and increased perfusion (Supplementary Fig. 3k–l). Thus, nitric oxide appears to provide collateral growth upon microcirculatory growth and maturation. This observation is complemented by the finding that direct T β 4 injection into the area of collateral growth (upper limb) does not improve perfusion to the same extent as

Figure 1 | MRTF activation and nuclear translocation induced angiogenesis via CCN1 and CCN2 activation. (a,b) MRTF-A transfection enhanced endothelial cell migration in a wound-scratch assay *in vitro* (red area = uncovered area, scale bar: 200 μm), and (c,d) tube formation of human microvascular endothelial cells (HMECs) *in vitro* (lpf = low-power field). Overexpression of Tβ4, a G-actin sequestering peptide activating MRTFs, displayed a similar effect unless an MRTF-shRNA was co-applied or a Tβ4 mutant (Tβ4 m), which lacked the G-actin-binding motif KLKKTET, were used (scale bar: 200 μm). (e) Tβ4 transfection of myocytic HL-1 cells enabled nuclear (blue fluorescence) translocation of MRTF-A (green fluorescence), an effect absent when the Tβ4 m construct was used lacking the G-actin-binding site (scale bar: 20 μm). (f) Tβ4 transfection of HL-1 cells induced an MRTF-SRF-sensitive luciferase reporter (containing three copies of the c-fos SRF-binding site = p3DA.Luc, cf.⁴⁴), unlike Tβ4 mutant transfection. (g) Tβ4-induced tube formation was abolished in case of shRNA-co-transfection of the MRTF/SRF target gene CCN1 (Cyr61, scale bar: 200 μm) (h,i). Tube maturation, assessed as pericyte recruitment (PC, green fluorescence) to endothelial rings (EC rings, red fluorescence, scale bar: 200 μm) was induced by MRTF-A and Tβ4. Co-transfection of shRNA versus the MRTF-target gene CCN2 (CTGF) abolished the Tβ4 effect. (All error bars: mean ± s.e.m., n = 5, *P < 0.05, **P < 0.001, using analysis of variance (ANOVA) with the Student-Newman-Keul's procedure)

remote injection of rAAV.Tβ4 into the lower limb, the site of microcirculatory growth (Supplementary Fig. 3e–i). These findings indicate that microvessel maturation and nitric oxide signalling are processes that have to occur in the sequence of MRTF-A-mediated vascular growth in order to accomplish functional vascular regeneration.

Efficacy of MRTF-A resolving hibernating myocardium.

Although peripheral and coronary arteries both perfuse muscle tissue, a unique feature of the heart muscle is its permanent contractile activity that requires continuous oxygen supply. A chronic decrease in oxygen supply alters the cellular composition of viable cardiomyocytes in the ischaemic area, resulting in a regional loss of contractile force called hibernating myocardium^{30,31}. Inside cardiomyocytes, hallmarks of hibernating myocardium are reduced myofilaments³² and mitochondria content as well as an increased glycogen content³³. Here we

studied the potential of MRTF-A to resolve dysfunction in hibernating myocardium because of percutaneous implantation of a reduction stent in pig hearts³⁴ inducing gradual occlusion of the Ramus Circumflexus (RCx, Supplementary Fig. 4a). At d28 after rAAV.MRTF-A application into the ischaemic area, significantly increasing MRTF-A tissue content (Supplementary Fig. 4b), we found a significantly higher degree of capillary density and pericyte coverage (Fig. 4a–c). Collateral growth and perfusion under rapid pacing (130 min⁻¹) were still impaired at d28—that is, before LacZ- and MRTF-A transduction (Supplementary Fig. 4c–f)—but improved at d56—that is, 4 weeks after MRTF-A-, and not LacZ transduction (Fig. 4d–f).

Enhanced collateral perfusion (Supplementary Fig. 4g) generated an improved functional reserve of the ischaemic area at rapid pacing (130 and 150 beats per minute, Fig. 4g). Concomitantly, we found an improved ejection fraction (EF) as marker of global systolic function (Fig. 4h, dynamic examples in Supplementary Fig. 4 and Supplementary video 1,2) and a decrease in the left

Figure 2 | Importance of MRTF signalling for neovascularization *in vivo*. (a) qRT-PCR analysis revealed an increase in MRTF-A in the rAAV.MRTF-A-transduced ischaemic hindlimb. (b) rAAV.MRTF-A induced MRTF/SRF target genes CCN1 and CCN2 *in vivo*. (c,d) rAAV.MRTF-A transduction increased capillary/muscle fibre ratio (c/mf), similar as the MRTF-activator Tβ4. rAAV.Tβ4 m, a mutant lacking the G-actin-binding domain, or co-application of Tβ4 and rAAV.MRTF-shRNA had no effect (PECAM-1 staining, scale bar: 100 μm). (e,f) Functionally, rAAV.MRTF-A and -Tβ4, but not rAAV.Tβ4 m or rAAV.Tβ4 + MRTF-shRNA, transduction improved hindlimb perfusion at d3 and d7 (e). (g) After rAAV.Cre vector-induced MRTFB deletion in MRTF-A-deficient mice (*Mrtf-a*^{-/-}/*b*^{flx/flx} + rAAV.Cre = MRTF-A/B^{-/-} Vi), Tβ4 transduction was not capable of inducing angiogenesis, as opposed to *Mrtf-a*^{+/-}/*b*^{flx/flx} (= MRTF-A/B^{+/-}) mice. (h) rAAV.Tβ4-increased perfusion was abolished in MRTF-A/B^{-/-} Vi mice. (i,j) In CCN1^{-/-} Vi mice (= CCN1^{flx/flx} + rAAV.Cre), the increase of capillary/muscle fibre ratio was abolished (PECAM-1 staining, scale bar: 100 μm), as was the gain of hindlimb perfusion (k,l). (All error bars: mean ± s.e.m., *n* = 5, **P* < 0.05, ***P* < 0.001, using ANOVA with the Student-Newman-Keul's procedure).

ventricular end diastolic pressure (Supplementary Fig. 4i), a prognostic marker of beginning heart failure.

Transgenic pigs ubiquitously and constitutively overexpressing Tβ4 (Supplementary Fig. 5) displayed similar capillary growth and maturation as rAAV-MRTF-A-treated animals (Fig. 4a–c). At d56, the blood flow reserve in the ischaemic area was increased (Fig. 4f), and functional reserve of either the ischaemic region (Fig. 4g) or the whole heart (Fig. 4h) was enhanced as in rAAV.MRTF-A-treated hearts. Of note, by virtue of the constitutive Tβ4 overexpression already from days 0 to 28, Tβ4tg animals did not experience a significant loss of perfusion nor myocardial function at rest or under rapid pacing (Fig. 4g, Supplementary Fig. 4d–g,i).

Moreover, rAAV.Tβ4-induced micro- and macrovascular growth and subsequent increases in perfusion reserve were abrogated, when an inhibitory MRTF-A-shRNA was co-applied (Fig. 5a–g). The gain of global (Fig. 5h, dynamic examples in Supplementary video 3,4) and regional myocardial function (Fig. 5i) was abolished when Tβ4 transduction was combined with MRTF-A inhibition by a suitable shRNA.

Discussion

Here using a combined genetic and physiological approach in mouse, rabbit and pig models, we show that MRTFs stimulate growth and maturation of microvessels as well as increased collateral blood flow upon arterial occlusion in hindlimb and coronary networks. Mechanistically, we demonstrate that MRTF translocation downstream of Tβ4 coactivates SRF inducing CCN1/CCN2 resulting in augmented angiogenesis and vascular smooth muscle cell recruitment and formation of functional vessels that can carry collateral flow (Fig. 6).

Of note, the relevance of the Thymosinβ4/MRTF-A/SRF pathway for microcirculatory growth was demonstrated, since deletion of *CCN1*, a gene induced by this transcriptional pathway, abrogated the gain of vascular structures and function *in vivo*. Moreover, in rabbit and pig models, we extend this notion to the formation of collaterals upon microcirculatory growth, a property not universal to vascular growth factors.

A key feature of MRTF-A activation is nuclear translocation upon reduction in G-actin levels, and nuclear export when G-actin abundance increases^{10,35}. Forced expression of MRTF-A

Figure 3 | Tβ4/MRTF-A-induced microvessel maturation is essential for collateral growth and improved perfusion. (a) HPLC analysis revealed a significant increase in Tβ4 protein after rAAV.Tβ4 transduction of ischaemic rabbit hindlimbs, whereas rabbit-specific Tβ4-Ala remained unchanged. (b–d) rAAV.MRTF-A or rAAV.Tβ4 application enhanced capillary density (PECAM-1 staining) as well as pericyte investment (NG2 staining, scale bar: 50 μm), which are both abolished by co-application of Angiopoietin-2 (rAAV.Ang2). (e,f) Angiographies of ischaemic hindlimbs on day 35 revealed an increased collateral formation in rAAV.MRTF-A- and rAAV.Tβ4-treated animals (red arrows indicate site of femoral artery excision, scale bar: 2 cm). Co-application of rAAV.Ang2 abolished this effect. (g) rAAV.MRTF-A and rAAV.Tβ4 induced a gain of perfusion in ischaemic hindlimbs, unless rAAV.Ang2 was co-applied. (all error bars: mean ± s.e.m., $n = 5$, * $P < 0.05$, ** $P < 0.001$, using ANOVA with the Student-Newman-Keul's procedure).

or Tβ4, a peptide activating MRTF-A by G-actin binding (Fig. 1), initiates an orchestrated micro- and macrocirculatory growth response in case of chronic peripheral (Figs 2 and 3) and heart (Fig. 4) muscle ischaemia. Consistently, chronic dysfunction of hibernating pig myocardium was resolved by either direct MRTF-A overexpression or MRTF-A activation via Tβ4 (Fig. 4). The notion that MRTF-A-SRF signalling provides myofilaments is of particular interest since a loss of actin cytoskeleton is a hallmark of hibernating myocardium caused by chronic coronary hypoperfusion³². Thus, MRTF-A is located at the crossroads of myocyte and vessel regeneration in hibernating myocardium. Tβ4, the most abundant G-actin-binding peptide of the cytosol, is capable of inducing vessel growth via endothelial migration and sprouting^{21,36}. An essential role of MRTF-A in Tβ4 angiogenic signalling was established *in vitro* and *in vivo*, since MRTF-A-shRNA was capable of abrogating endothelial migration and sprouting (Fig. 1b,d) as well as micro- and macrovascular growth (Fig. 2d,f) and functional cardiac improvement (Supplementary Fig. 6). Accordingly, endothelial-specific deficiency of MRTFs caused incomplete formation of the primary vascular plexus of the developing retina²⁶. Moreover, SRF, the main target of MRTF-A, has recently been identified as crucial for tip

cell behaviour in sprouting angiogenesis upon VEGF-A stimulation²⁵. Nevertheless, VEGF-A results in growth of immature and unstable capillaries³⁷, as opposed to Tβ4-MRTF-A, pointing to a difference in signalling of both vessel growth factors.

A particular feature of the Tβ4-MRTF-A-SRF signalling axis is the balanced nature of vascular growth—that is, microvessel growth and maturation as well as adaptive collateralization. Surprisingly, angiopoietin-2 not only abrogated pericyte investment after MRTF-A- or Tβ4 treatment (Fig. 3b,c) but also compromised adaptive collateralization (Fig. 3e–g). Thus, microcirculatory maturation appears to be essential for the transmission of collateral growth signals. The role of the microvascular compartment is additionally underscored by the observation that local i.m. treatment of the collateral compartment (upper limb in rabbits) does not provide an equivalent vascular regeneration to local i.m. treatment of the microvascular compartment (lower limb, Supplementary Fig. 3g–i). An essential signal, sent from the microvascular compartment to induce adaptive collateral growth, appears to be nitric oxide, since the unselective nitric oxide synthase inhibitor L-NAME abrogated the arteriogenic effect of Tβ4. Of note, L-NAME did not affect capillary sprouting nor

Figure 4 | MRTF-A improves collateral formation and perfusion in the hibernating pig myocardium. (a–c) In hibernating porcine myocardium (cf. Supplementary Fig. 4a), rAAV.MRTF-A transduction as well as ubiquitous overexpression of Tβ4 (Tβ4tg, cf. Supplementary Fig. 5) induced capillary sprouting (PECAM-1 staining, scale bar: 50 μm) as well as pericyte investment (NG2 staining). (d,e) Moreover, collateral growth was detected in rAAV.MRTF-A-transduced hearts, similar to Tβ4tg hearts (scale bar: 2 cm). (f) Regional flow reserve, obtained at rapid atrial pacing (130 beats per minute), was found to be increased in rAAV.MRTF-A-transduced and Tβ4-transgenic hearts. (g) Regional myocardial function, assessed by subendocardial segment shortening at rest and under atrial pacing (130 and 150 beats per minute), revealed an improved functional reserve by either via rAAV.MRTF-A transduction or in Tβ4tg hearts. (h) Ejection fraction, a parameter of global myocardial function, improved in rAAV.MRTF-A-transduced animals on day 56 compared with day 28. In contrast, constitutively Tβ4-overexpressing animals (Tβ4tg) displayed no loss of function on day 28. (All error bars: mean ± s.e.m., $n = 5$, * $P < 0.05$, ** $P < 0.001$, using ANOVA with the Student-Newman-Keul's procedure).

pericyte to endothelial cell ratio in Tβ4-treated hindlimbs (Supplementary Fig. 3j–l). These experiments indicate a hierarchical order in the balanced vascular growth process induced by the Tβ4-MRTF-A-SRF axis, which originates in the microvasculature and progresses to subsequent collateralization.

Collectively, our data demonstrate that activation of Tβ4-MRTF augments collateral blood flow in ischaemic heart and hindlimb via induction of CCN1/CCN2. At the cellular level this response involves endothelial sprouting via CCN1 (CYR61)²⁹ and maturation—that is, pericyte investment—via CCN2 (CTGF)²⁴ resulting in a stable and functional vascular network that can carry collateral blood flow and improve conductance. Pericyte investment is crucial herein since Ang 2, by virtue of disrupting pericyte investment³⁸, abolished the positive effects exerted by Tβ4-MRTF signalling (Fig. 3). This finding indicates the central role of vessel maturation and balanced vessel growth and paves new therapeutic avenues towards functional neovascularization.

Methods

Reagents. All cell culture media and chemicals were purchased from Sigma (Deisenhofen, Germany) if not indicated otherwise. Contrast agent Solutrast 370

was provided by Byk Gulden (Konstanz, Germany). CCN1-shRNA (Cyr61-shRNA, sc-39332) and CCN2-shRNA (CTGF-shRNA, sc-39329) were purchased from Santa Cruz Biotechnology, CA, USA.

Adeno-associated viral vectors. The recombinant rAAV.MRTF-A, rAAV.Tβ4, rAAV.Tβ4m, rAAV.LacZ, rAAV.Cre and rAAV.MRTF-shRNA (5'-GATCCCGCATGGAGCTGGTGGAGAAGAATTCAAGAGATTCTTCTCCACCAGCTCCATGTTTTGGAAA-3') vectors were produced using triple transfection of U293 cells. One plasmid encoded the transgene under control of a CMV promoter flanked by *cis*-acting AAV2 internal terminal repeats, a second plasmid provided AAV2 rep and AAV9 cap in *trans*³⁹, whereas a third plasmid (delta F6) supplemented adenoviral helper function. Cells were harvested 48 h later and vectors purified with caesium gradients⁴⁰. Viral titres were determined using RT-PCR against the polyA tail of the vector bGH (primer sequence see Table 1). *Trans* and helper plasmids were kindly provided by James M. Wilson, University of Pennsylvania.

Cell culture. Satisfaction (TPP AG, Trasadingen, Schweiz) was used for the transfection of human microvascular endothelial cells (HMECs, CDC, North Carolina, USA), murine endothelial cells (bEnd.3, CRL-2299, ATCC, USA) and myocytic cell line (HL-1 cells, kindly provide by Dr W. Claycomb) according to the manufacturer's instructions. Here 100 μl serum- and antibiotic-free DMEM medium were mixed with 3 μl Satisfaction transfection agent.

Figure 5 | MRTFs are required for Tβ4-induced cardioprotection. (a,b) rAAV.Tβ4 induced capillary growth (PECAM-1 staining) and (c) pericyte investment (NG2 staining; scale bar: 50 μm), unless co-application of rAAV.MRTF-shRNA abrogated both processes. (d,e) Collateral growth was detected in rAAV.Tβ4-transduced animals but not after co-application of rAAV.MRTF-shRNA (scale bar: 2 cm). (f) Rentrop score revealed an enhanced collateralization after rAAV.Tβ4 transduction, except in case of MRTF-A-shRNA co-application. (g) Regional myocardial blood flow at flow reserve (atrial pacing 130 min⁻¹) improved in rAAV.Tβ4-treated animals but not in rAAV.Tβ4 + MRTF-shRNA hearts. (h) Analysis of ejection fraction revealed an improvement of systolic myocardial function in rAAV.Tβ4-transduced animals (d56), compared with day 28 (day of transduction). No gain of ejection fraction was found in rAAV.Tβ4 + MRTF-shRNA-treated hearts. (i) Regional myocardial function, assessed by subendocardial segment shortening at rest and under atrial pacing (130 and 150 bpm), reveals an increased functional reserve after rAAV.Tβ4-, but not rAAV.Tβ4 + MRTF-shRNA transduction. (All error bars: mean ± s.e.m., n = 5, *P < 0.05, **P < 0.001, using t-test for comparison of two groups or ANOVA with the Student-Newman-Keul's procedure for multiple group comparison).

In vitro tube formation and coculture experiments. For matrigel experiments, HMECs were transfected with pcDNA, MRTF-A, Tβ4 ± MRTF-shRNA (5'-GATC CCCGCATGGAGCTGGTGGAGAAGAATTCAAGAGATTCTCTCCACCAG CTCCATGTTTTGGAAA-3'), Tβ4 m (which lacked the G-actin-binding motif KLKKTET)⁴¹ or Tβ4 ± CCN1-shRNA. Cells (8,000 cells per well) were seeded on matrigel (BD Matrigel Basement Membrane Matrix, BD Biosciences, USA) in basal endothelial growth medium with a 5% fetal bovine serum addition and pictures were taken after 18 h. Number of rings per low-power field was quantified.

In coculture experiments, HL-1 cells were transduced by a rAAV-Tβ4 ± CCN1-shRNA, rAAV.MRTF-shRNA or rAAV-Tβ4 m (1 × 10⁶ AAV6 particles per cell). HL-1 and matrigel-embedded HMECs (8,000 cells per well) were physically separated by a permeable membrane. After 18 h, HL-1 cells were removed and ring formation per low-power field was quantified.

Pericytic CH3/10T1/2 cell (CCL-226, ATCC, USA) attraction to murine endothelial cells (bEnd.3) was assessed after transfecting the endothelial compartment with pcDNA, MRTF-A or Tβ4 ± CCN2-shRNA using Satisfaction (Agilent, Boeblingen, Germany). Endothelial cells were stained DiD (red, Vybrant) and seeded on matrigel (12,000 cells per well). After 6 h DiO (green, Vybrant)-stained pericyte-like cells (2,000 cells per well) were added and migration towards tubes was allowed for 2 h. Then, coculture pictures were taken using confocal laser microscopy (Carl Zeiss, Jena, Germany).

Migration assay. HMEC cells were transfected with the indicated transgenes, as described above. A total of 60,000 cells were grown to confluence in wells carrying a strip-like insert (ibidi, Munich, Germany). After 24 h, the insert was removed. Images were taken at the time points 0 and 22 h at a 10-fold magnification (low-power field), and the uncovered area analysed (Image J 1.43u, National Institute of Health (NIH), USA).

HL-1 cell staining. Cardiomyocytic HL-1 cells were transduced by AAVs encoding for the indicated transgenes. Then, cells were plated on μ dishes (ibidi). After 48 h, nuclei were stained with Syto62. After fixation of the cells with PFA (2%), they were permeabilized and incubated with an MRTF-A antibody (1:200, Santa Cruz Biotechnology) and a secondary antibody (1:200, Alexa 488, Invitrogen, Karlsruhe, Germany). Pictures were taken using confocal laser microscopy (Carl Zeiss), and the mean fluorescence intensity of the area of 100 nuclei, identified via Syto62, was automatically assessed with its LSM5 image browser.

High-performance liquid chromatography (HPLC) analysis. The determination of Tβ4 was performed via HPLC analysis⁴². Briefly, tissue samples were destructed by adding 4 M perchloric acid containing 1% Thiodiethanol to a final concentration

Figure 6 | Mechanisms of MRTF-mediated therapeutic neovascularization. MRTF-A or Tβ4 transduction induces an increased amount of MRTF-A unbound to G-actin, which after translocation to the nucleus interacts with SRF, inducing, for example, CCN1 and CCN2 as target genes. CCN1 enables capillary growth (angiogenesis), whereas CCN2 enhances the pericyte investment (vessel maturation). Together, these mechanisms induce collateral growth in a nitric oxide-dependent manner leading to a therapeutic neovascularization.

Table 1 Primer sequences used for PCR were as follows.		
BGH		
Forward	5'-TCTAGTTGCCAGCCATCTGTTGT-3'	
Reverse	5'-TGGGAGTGGCACCTTCCA-3'	
GAPDH		
Forward	5'-AATTCAACGGCAGTCAAG-3'	
Reverse	5'-ATGGTGGT-GAAGACACCACT-3'	
Tβ4		
Forward	5'-TCATCGATATGTCTGACAAAC-3'	
Reverse	5'-CAGCTTGCTTCTCTTGTTCAA-3';	
MRTF-A		
Forward	5'-AATCCATGGGTCGACGGTATCGAT-3'	
Reverse	5'-ATACCATGGTCAGGCACCGGGCTT-3'	
CCN1 (CYR61)		
Forward	5'-GCTAAACAACCTCAACGAGGA-3'	
Reverse	5'-GGCTGCAACTGCGTCTCTCTG-3'	
CCN2 (CTGF)		
Forward	5'-CCCTAGCTGCCTACCGACT-3'	
Reverse	5'-CATTCCACAGGTCTTAGAACAGG-3'	
Ang2		
Forward	5'-TCGAATACGATGACTCGGTG-3'	
Reverse	5'-GTTTGTCCCTATTCTATC-3'	

of 0.4 M. Mixtures were homogenized, incubated at 4 °C for 30 min and centrifuged for 10 min at 20,000 g. The supernatant was analysed using reverse-phase chromatography. In rabbits, endogenous and exogenous Tβ4 were distinguished by detection of the rabbit-specific Tβ4-Ala.

Luciferase assay. For determining the MRTF-dependent luciferase activity, HMEC and HL-1 cells were transfected with p3DA.Luc, an SRF reporter gene (a construct of a synthetic promoter with three copies of the c-fos SRF-binding site and a *Xenopus* type 5 actin TATA box plus a transcription start site inserted into pGL3 = p3DA.Luc)⁴³ and 930 ng of either pcDNA, Tβ4 or a Tβ4 mutant lacking the G-actin-binding site. Comparable transfection efficacy was assured by co-transfection of 50 ng ptkRL (Renilla luciferase reporter). Cell pellets were lysed, further purified by centrifugation for 10 min at 4 °C and 13,000 r.p.m. and utilized for assessment of firefly luciferase activity and Renilla luciferase activities, which are given as ratio firefly luciferase/renilla activity⁴³.

RNA modulation and detection. Real-time (RT)-PCR was performed with SYBR green dye (iQ SYBR Green supermix, Bio-Rad, Munich, Germany) and measured on an iQ-Cycler (Bio-Rad). RT-PCR was performed with primers mentioned in Table 1. Expression levels were normalized to GAPDH and displayed as fold change to the pcDNA control situation. The comparative 2-ΔΔC_t method was carried out, calculating the delta C_t values for the gene of interest and the housekeeping gene and then calculating the difference between both delta C_t values⁴⁴.

Western blot analysis MRTF-A. For analysis of total MRTF-A protein, cell culture and tissue samples were homogenized in 1 ml lyses buffer containing 20 mM Tris, 1 mM EDTA, 140 mM NaCl, 1% Nonidet P-40 (NP-40), 0.005 mg ml⁻¹ leupeptin, 0.01 mg ml⁻¹ aprotinin, 1 mM PMSF, pH 7.5. Whole protein extracts (60 μg) were resolved on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the proteins were electrotransferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA), blocked with 5% nonfat milk in PBS-0.1% Tween-20 buffer (PBS-T) and incubated overnight at 4 °C with primary antibodies against the MRTF-A (C-19, 1:125, Santa Cruz Biotechnology). After washing of the membrane, a secondary antibody (donkey anti-goat IgG 1:5,000, horseradish peroxidase-conjugated, Santa Cruz

Biotechnology) was incubated and the membrane was developed with a chemiluminescence reagent (ECL, Detection Reagents, GE Healthcare, Buckinghamshire, UK). For analysis of the nuclear versus the cytosolic MRTF-A protein content, separation was performed with the Ne-Per nuclear and cytoplasmic extraction reagents (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's instructions. After that western blot analysis was performed, as described above. As control protein either alpha Tubulin (6A204, 1:500, Santa Cruz Biotechnology) or for the nuclear fraction Lamin B1 (ZL-5, 1:500, Santa Cruz Biotechnology) was used. Full-length images of immunoblots are shown in Supplementary Fig. 6.

Animal experiments. Animal care and all experimental procedures were performed in strict accordance to the German and NIH animal legislation guidelines and were approved by the Bavarian Animal Care and Use Committee (AZ 55.2-1-54-2531-26/09, 130/08, 140/07). All animal experiments were conducted at the Walter Brendel Centre of Experimental Medicine.

Murine hindlimb ischaemia. Unilateral hindlimb ischaemia of the right leg⁴⁵ was performed in male age-matched C57Bl6 mice (6–8 weeks of age, Charles River, Sulzfeld, Germany) as well as in MRTF-A^{+/−}B^{fl/fl}, MRTF-A^{−/−}B^{fl/fl}, MRTF-A^{+/−}B^{−/−}Vi (= MRTF-A^{+/−}B^{fl/fl} + 3 × 10E12 rAAV.cre), MRTF-A^{−/−}B^{−/−}Vi (= MRTF-A^{−/−}B^{fl/fl} + 3 × 10E12 rAAV.cre) and CCN1^{fl/fl} mice as well as CCN1^{−/−}Vi mice (= CCN1^{fl/fl} ± rAAV.cre), generated in the laboratory of Ralf Adams, presented unpublished). Before induction of ischaemia (day −14), 3 × 10¹² rAAV virus particles were applied intramuscularly to the right leg as indicated⁴⁶. On day 0 the left leg underwent sham operation, whereas the femoral artery was ligated in the right leg. The post-ischaemic blood flow recovery was conducted using laser doppler flow cytometry (Moor Instruments, Devon, UK). Measurements were assessed directly before and after surgery, as well as on days 3 and 7. Results are given as right to left leg ratio including subtraction of background tissue value. RT-PCR and HPLC analyses were performed on day 5 after ischaemia induction; tissue was harvested from treated and non-treated legs. Analyses of capillary density and vessel maturation were performed on day 7 in all groups via PECAM-1 (sc1506, 1:50, Santa Cruz Biotechnology) and NG-2 (in MRTF-A^{+/−}B^{fl/fl} mice, 1:200, Chemicon, Nürnberg, Germany) staining in frozen tissue samples of the musculus gastrocnemius and musculus adductor.

Rabbit hindlimb ischaemia. In female rabbits, 2–2.5 kg body weight, on day 0 the complete femoral artery of the right leg was excised⁴⁴ and rAAV application (5 × 10¹² virus particles) was performed via i.m. injection into the right limb as indicated. On days 7 and 35, angiography was performed by injection of contrast agent (Solutrast 370, Byk Gulden) into the ischaemic limb with an automatic injector (Harvard Apparatus, Freiburg, Germany). Furthermore, fluorescent microspheres (15 µm, Molecular Probes, Eugene, OR, USA) were applied for blood flow measurements in the ischaemic and non-ischaemic tissues. For blood flow analysis, tissue samples were digested as described earlier.^{1,47} Fluorescence analysis was performed via Tecan Saphire 2 microplate reader for the emission wavelengths 680, 638, 598, 545, 515, 468 and 424 nm, depending on the fluorescent colour used. Blood flow is given as percentage day 7, right to left leg⁴⁸. Analyses of capillary density and vessel maturation were performed via PECAM-1 (sc1506, 1:50, Santa Cruz Biotechnology) and NG-2 (1:200, Chemicon) staining in frozen tissue samples (lower limb only) of the ischaemic and non-ischaemic limbs.

Pig chronic myocardial ischaemia. Three-month-old, male pigs were anaesthetised and arteria carotis communis as well as vena jugularis externa are instrumented⁴⁹. Briefly, a PTFE membrane-covered restrictor stent was implanted in the proximal RCx, leading to a 75% reduction in blood flow. Correct localization of the stent and patency of the distal vessel was ensured by injection of contrast agent⁴⁹. On day 28, baseline measurements were obtained for global myocardial function (left ventricular end diastolic pressure, EF) and myocardial perfusion (fluorescent microspheres, 15 µm, Molecular Probes). After that, selective pressure-regulated retroinfusion into the great cardiac vein draining the RCx-perfused myocardium was performed for 5 × 10¹² virus particles rAAV.MRTF-A and rAAV.Tβ4 ± rAAV.MRTF-shRNA. On day 56 measurements for global myocardial function and blood flow were repeated and regional myocardial function of the ischaemic and non-ischaemic areas were obtained (at rest and under rapid pacing, 130 and 150 bpm). A post-mortem angiography was performed for collateral score calculation and Rentrop score analysis (0 = no filling, 1 = side branch filling, 2 = partial main vessel filling, 3 = complete main vessel filling). Tissue was harvested for regional myocardial blood flow analysis and immunohistology.

Global myocardial function. On days 28 and 56, global myocardial function (left ventricular end diastolic pressure) was assessed with Millar pressure tip catheter (Sonometrics, Ontario, Canada). A left ventricular angiogram for global myocardial function was performed on days 28 and 56. EF was obtained with planimetry of end systolic and end diastolic angiogram pictures (Image J 1.43u, NIH).

Regional myocardial function. On day 56, after induction of ischaemia, sternotomy was performed and ultrasonic crystals were placed subendocardially in the non-ischaemic area (LAD control region) as well as in the ischaemic area (Cx perfused area) in a standardized manner. Subendocardial segment shortening (Sonometrics) was assessed at rest and under increased heart rates (functional reserve, pacing 130 and 150 bpm) and evaluated offline (electrocardiogram-dependent).

Regional myocardial blood flow. Analysis of the regional myocardial blood flow was performed on day 28 (before rAAV treatment) and day 56 (28 days after rAAV treatment) via fluorescent microspheres (Molecular Probes). The microspheres (15 µm, 5 × 10⁶ particles per injection) were injected via a pigtail catheter into the left ventricle. Blood flow measurements were performed at rest and under increased heart rate (130 bpm). Fluorescence content was analysed via Tecan Saphire 2 micro plate reader and calculation of the regional myocardial blood flow was performed, either as ml g^{−1} tissue absolute or as the ratio to the non-ischaemic region at rest (blood flow % non-ischaemic)^{1,50}.

Histology. Tissue samples of the ischaemic and non-ischaemic areas were analysed for capillary density (PECAM-1-positive cells, red) and pericyte investment (NG2-positive cells, green). Staining for capillaries was performed with a CD31 (PECAM-1)-antibody (1:200, SC1506, Santa Cruz Biotechnology) and a Rhodamin-labelled secondary antibody (1:50, SC2092, Santa Cruz Biotechnology), whereas the vessel maturation was quantified by pericyte (NG2 antibody, 1:200, AB5320 Millipore) co-staining. Pictures of the ischaemic and non-ischaemic regions were taken with high-power field magnification (40-fold) and five independent pictures per region (ischaemic and non-ischaemic) and per animal were quantified.

rAAV transduction efficacy. For evaluation of the rAAV transduction efficacy, the control mice, rabbit and pigs were treated with rAAV.LacZ. Cryosections of the LacZ-transduced animals were performed and stained for beta-galactosidase (blue staining). Furthermore, RT-PCR for the different transgenes was performed using the primers described in Table 1 and was analysed as described above.

Tomato mice. These mT (membrane-targeted tdTomato)/mG (membrane-targeted enhanced green fluorescent protein) homozygous expressing mice (Jackson Laboratory, Bar Harbor, ME, USA) carry loxP sites on both sides of the mT and mG encoding sequence. Cre expression via rAAV.cre for virus transduction efficacy deleted the mT (red fluorescence) in the cells and allowed for eGFP expression (green fluorescence) in the same cells (Supplementary Fig. 2b).

Statistical methods. The results are given as mean values ± s.e.m. Statistical analysis for comparison of two groups was performed with Student's *t*-test. Statistical analyses for multiple comparisons were performed using one-way analysis of variance. Whenever a significant effect was obtained (*P* < 0.05), we used multiple comparison tests between the groups with the Student–Newman–Keul's procedure (IBM SPSS 19.0, IBM Chicago, IL, USA). Differences between groups were considered significant for *P* < 0.05.

References

- Kupatt, C. *et al.* Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion: role of vessel maturation. *J. Am. Coll. Cardiol.* **56**, 414–422 (2010).
- Rissanen, T. T. & Yla-Herttuala, S. Current status of cardiovascular gene therapy. *Mol. Ther.* **15**, 1233–1247 (2007).
- Jain, R. K. Molecular regulation of vessel maturation. *Nat. Med.* **9**, 685–693 (2003).
- Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. *Cell* **146**, 873–887 (2011).
- van Royen, N. *et al.* START Trial: a pilot study on stimulation of arteriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. *Circulation* **112**, 1040–1046 (2005).
- Schierling, W. *et al.* The role of angiogenic growth factors in arteriogenesis. *J. Vasc. Res.* **46**, 365–374 (2009).
- Smith, A. H. *et al.* Sustained improvement in perfusion and flow reserve after temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 plasmid deoxyribonucleic acid. *J. Am. Coll. Cardiol.* **59**, 1320–1328 (2012).
- Tirziu, D. *et al.* Endothelial nuclear factor-kB dependent regulation of arteriogenesis and branching. *Circulation* **126**, 2589–2600 (2012).
- Wang, D. Z. *et al.* Potentiation of serum response factor activity by a family of myocardin-related transcription factors. *Proc. Natl Acad. Sci. USA* **99**, 14855–14860 (2002).

10. Miralles, F., Posern, G., Zaromytidou, A. I. & Treisman, R. Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell* **113**, 329–342 (2003).
11. Medjkane, S., Perez-Sanchez, C., Gaggioli, C., Sahai, E. & Treisman, R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. *Nat. Cell Biol.* **11**, 257–268 (2009).
12. Olson, E. N. & Nordheim, A. Linking actin dynamics and gene transcription to drive cellular motile functions. *Nat. Rev. Mol. Cell Biol.* **11**, 353–365 (2010).
13. Kuwahara, K. *et al.* Modulation of adverse cardiac remodeling by STARS, a mediator of MEF2 signaling and SRF activity. *J. Clin. Invest.* **117**, 1324–1334 (2007).
14. Ho, C. Y., Jaalouk, D. E., Vartiainen, M. K. & Lammerding, J. Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. *Nature* **497**, 507–511 (2013).
15. Wang, D. Z. *et al.* Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. *Cell* **105**, 851–862 (2001).
16. Kuwahara, K., Barrientos, T., Pipes, G. C. T., Li, S. & Olson, E. N. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. *Mol. Cell Biol.* **25**, 3173–3181 (2005).
17. Mouilleron, S., Langer, C. A., Guettler, S., McDonald, N. Q. & Treisman, R. Structure of a pentavalent G-actin*MRTF-A complex reveals how G-actin controls nucleocytoplasmic shuttling of a transcriptional coactivator. *Sci. Signal* **4**, ra40 (2011).
18. Philp, D., Huff, T., Ghosh, Y. S., Hannappel, E. & Kleinman, H. K. The actin binding site on thymosin beta4 promotes angiogenesis. *FASEB J.* **17**, 2103–2105 (2003).
19. Huff, T. *et al.* Nuclear localisation of the G-actin sequestering peptide thymosin [beta]4. *J. Cell Sci.* **117**, 5333–5341 (2004).
20. Morita, T. & Hayashi, K. i. G-actin sequestering protein thymosin-β4 regulates the activity of myocardin-related transcription factor. *Biochem. Biophys. Res. Commun.* **437**, 331–335 (2013).
21. Grant, D. S. *et al.* Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. *J. Cell Sci.* **108**, 3685–3694 (1995).
22. Latinkic, B. V., O'Brien, T. P. & Lau, L. F. Promoter function and structure of the growth factor-inducible immediate early gene *cyr61*. *Nucleic Acids Res.* **19**, 3261–3267 (1991).
23. Muehlich, S. *et al.* Actin-dependent regulation of connective tissue growth factor. *Am. J. Physiol.* **292**, C1732–C1738 (2007).
24. Hall-Glenn, F. *et al.* CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. *PLoS ONE* **7**, e30562 (2012).
25. Franco, C. A. *et al.* SRF selectively controls tip cell invasive behavior in angiogenesis. *Development* **140**, 2321–2333 (2013).
26. Weinl, C. *et al.* Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae. *J. Clin. Invest.* **123**, 2193–2206 (2013).
27. Leitner, L. *et al.* MAL/MRTF-A controls migration of non-invasive cells by upregulation of cytoskeleton-associated proteins. *J. Cell Sci.* **124**, 4318–4331 (2011).
28. Geneste, O., Copeland, J. W. & Treisman, R. LIM kinase and Diaphanous cooperate to regulate serum response factor and actin dynamics. *J. Cell Biol.* **157**, 831–838 (2002).
29. Hanna, M. *et al.* Mechanical regulation of the proangiogenic factor CCN1/CYR61 gene requires the combined activities of MRTF-A and CREB-binding protein histone acetyltransferase. *J. Biol. Chem.* **284**, 23125–23136 (2009).
30. Heusch, G. & Schulz, R. Hibernating myocardium: a review. *J. Mol. Cell Cardiol.* **28**, 2359–2372 (1996).
31. Nagueh, S. F. *et al.* Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans. *Circulation* **100**, 490–496 (1999).
32. Bito, V. *et al.* Reduced force generating capacity in myocytes from chronically ischemic, hibernating myocardium. *Circ. Res.* **100**, 229–237 (2007).
33. St Louis, J. D. *et al.* An experimental model of chronic myocardial hibernation. *Ann. Thorac. Surg.* **69**, 1351–1357 (2000).
34. Kupatt, C. *et al.* Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. *J. Am. Coll. Cardiol.* **49**, 1575–1584 (2007).
35. Vartiainen, M. K., Guettler, S., Larijani, B. & Treisman, R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. *Science* **316**, 1749–1752 (2007).
36. Smart, N. *et al.* Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. *Nature* **445**, 177–182 (2007).
37. Dor, Y. *et al.* Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. *EMBO J.* **21**, 1939–1947 (2002).
38. Ziegler, T. *et al.* Angiotensin 2 mediates microvascular and hemodynamic alterations in sepsis. *J. Clin. Invest.* **123**, 3436–3445 (2013).
39. Bish, L. T. *et al.* Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. *Hum. Gene Ther.* **19**, 1359–1368 (2008).
40. Lehrke, M. *et al.* Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. *Cell Metab.* **1**, 297–308 (2005).
41. Bednarek, R. *et al.* Ku80 as a novel receptor for thymosin beta4 that mediates its intracellular activity different from G-actin sequestering. *J. Biol. Chem.* **283**, 1534–1544 (2008).
42. Huff, T., Muller, C. S. & Hannappel, E. Thymosin beta4 is not always the main beta-thymosin in mammalian platelets. *Ann. N.Y. Acad. Sci.* **1112**, 451–457 (2007).
43. Posern, G., Sotiropoulos, A. & Treisman, R. Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. *Mol. Biol. Cell* **13**, 4167–4178 (2002).
44. Pfosser, A. *et al.* Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. *Cardiovasc. Res.* **65**, 728–736 (2005).
45. Limbourg, A. *et al.* Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. *Nat. Protoc.* **4**, 1737–1748 (2009).
46. Qin, D. *et al.* Early vessel destabilization mediated by Angiotensin-2 and subsequent vessel maturation via Angiotensin-1 induce functional neovascularization after ischemia. *PLoS ONE* **8**, e61831 (2013).
47. Thein, E., Raab, S., Harris, A. G. & Messmer, K. Automation of the use of fluorescent microspheres for the determination of blood flow. *Comput. Methods Programs Biomed.* **61**, 11–21 (2000).
48. Leberer, C. *et al.* Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion. *Endothelium* **10**, 257–265 (2003).
49. von, G. D. *et al.* Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. *J. Am. Coll. Cardiol.* **42**, 1120–1128 (2003).
50. Hinkel, R. *et al.* Angiogenic potential of Ad2/Hif-1alpha/VP16 after regional application in a preclinical pig model of chronic ischemia. *Curr. Vasc. Pharmacol.* **11**, 29–37 (2013).

Acknowledgements

We specially thank Tien Cuong Kieu and Elisabeth Raatz for their excellent technical assistance. We thank Cosimo Michele Picciolo and Christina Kuebel for their assistance with the MRI. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, KU 1019/10-1 to C.K., SFB/TR 127 B.P., B.R., H.N., R.H.A. and C.K.), the DZHK and the German Ministry of Education and Research (BMBF to D.T., F.L.N., B.R., O.J.M., C.W. and C.K.), the Deutsche Krebshilfe (to A.N.), as well as the Else-Kröner-Fresenius Foundation (2009_A61 to C.K. and R.H.), the Fritz-Bender stiftung (to E.D.) and FöFoLe grants of the Ludwig-Maximilians University (to R.H., T.T. and W.H.).

Author contributions

R.H. and C.K. conceived the project, designed and performed experiments, coordinated collaborations and wrote the manuscript. T.T., W.H. and F.G. performed the experiments. S.L. cloned the rAAV constructs. B.P. and H.N. developed and produced the transgenic pigs. D.T. performed and analysed the MRI in the pigs. R.H.A., C.W., A.N. and E.O. provided the transgenic mice. L.L., G.P. provided the MRTF constructs and analysed the MRTF assays. O.J.M. designed and provided the cre vector and interpreted the data. C.C. designed and provided the constructs for the TB4 mutant. E.H. performed and analysed the HPLC assays. I.B.-M., P.B., F.N., B.R., C.W. and E.D. provided technical support, conceptual advice, interpreted results and critically reviewed the manuscript.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Hinkel, R. *et al.* MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2. *Nat. Commun.* **5**:3970 doi: 10.1038/ncomms4970 (2014).